Anavex Life Sciences Corp. carries no debt; cash flow comfortably covers obligations.

Anavex Life Sciences Corp.'s free cash flow has decreased 26.72% from $-30.81M last year to $-39.04M, signaling decreasing performance

Anavex Life Sciences Corp.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Anavex Life Sciences Corp. has insufficient data to evaluate this check.

Anavex Life Sciences Corp. has negative EBITDA, making leverage ratio unreliable

Anavex Life Sciences Corp. earns at least as much interest as it pays. Interest obligations are fully covered.

Anavex Life Sciences Corp. has insufficient data to evaluate this check.

Anavex Life Sciences Corp.'s short-term assets of $103.81M exceed its short-term liabilities of $8.95M

Anavex Life Sciences Corp.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Anavex Life Sciences Corp.'s return on equity of -38.76%, is lower than 15.00%, indicating bad performance

Anavex Life Sciences Corp.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Anavex Life Sciences Corp. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Anavex Life Sciences Corp. has negative free cash flow, indicating the company is burning cash rather than generating it

Anavex Life Sciences Corp. has negative free cash flow, indicating cash burn

Anavex Life Sciences Corp.'s yearly earnings has decreased 7.85% since last year from $-43.00M to $-46.38M, signaling decreasing performance

Anavex Life Sciences Corp.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -35.22% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Anavex Life Sciences Corp. has insufficient revenue history to calculate 3-year revenue CAGR.

Anavex Life Sciences Corp. had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance

Anavex Life Sciences Corp. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Anavex Life Sciences Corp. has insufficient data to evaluate this check.

Anavex Life Sciences Corp. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Anavex Life Sciences Corp. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Anavex Life Sciences Corp. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Anavex Life Sciences Corp. has insufficient data to evaluate this check.

Anavex Life Sciences Corp. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Anavex Life Sciences Corp. has a price-to-book ratio of 1.84x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Anavex Life Sciences Corp. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue